In drug development news, FDA granted accelerated approval for Boehringer’s Hernexeos (zongertinib) as a first-line HER2-mutant non-small cell lung cancer treatment in just 44 days, utilizing the ...

Q4 2025 earnings call: cash runway to Q2 2028, OpRegen site expansion, AlloSCOPE progress—read key takeaways now.

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...

As funding constraints and shifting investment priorities reshape the CGT landscape, the importance of building resilient, collaborative frameworks is evident.

Amatera’s approach is “2x faster and 10x more cost-effective” than industry standards for developing new varieties of perennials, it claims.

Proteomics-informed, genome-edited CHO design increased productivity up to three-fold and titers two-fold, strengthening CLD for novel biologics and biosimilars. Extended culture robustness was ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

LiCellGrow was developed to assist therapy developers in determining the optimal culture conditions during process ...

PHCbi will exhibit LiCellGrow™ at the 25th Congress of the Japanese Society for Regenerative Medicine, March 19-20 at the Kobe International Conference Center and Kobe International Exhibition Center ...

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and ...

As key molecules on the surface of immune cells, Fc receptors are the core hub of antibody-mediated effector functions. They play an irreplaceable role in physiological processes such as ...